Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Janssen Research & Development, LLC
Hoffmann-La Roche
Bristol-Myers Squibb
Incyte Corporation
University of California, Irvine
Neonc Technologies, Inc.
Tizona Therapeutics, Inc
Massachusetts General Hospital
Incyte Corporation
Charite University, Berlin, Germany
Abramson Cancer Center at Penn Medicine
University of Alabama at Birmingham
Sapience Therapeutics
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Biotheus Inc.
Catharina Ziekenhuis Eindhoven
Celyad Oncology SA